Sign up to save your podcasts
Or
Share Selecting Therapy for ER+/HER2- Metastatic Breast Cancer: Key Factors to Consider
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Selecting Therapy for ER+/HER2- Metastatic Breast Cancer: Key Factors to Consider
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Megan Kruse, MD
From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.
View all episodes
By ReachMD
4.5
22 ratings
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Megan Kruse, MD
From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.